Company / FCF Margin
Intellia Therapeutics, Inc. FCF Margin History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-585.0%
FY2025
5-year range
-1124.9% / -585.0%
FY2021-FY2025
Trend
+4.5%
vs FY2024
Sector context
#136 of 139
Health Care
What the data says
Among 139 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 2% for fcf margin. FCF Margin has fluctuated over the past 8 years, ranging from -1124.9% in FY2023 to -92.3% in FY2020.
Based on SEC 10-K filings.
-585.0% in FY2025 with a 5-year CAGR of -492.7%.
Improved from -1124.9% to -585.0% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +80.5pp
- 5-Year Change
- -492.7pp
- 10-Year Change
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 139This company -585.0% Sector average -217.0%
▼
-169.6% below sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 4.5% year-over-year.
- Currently 368.0pp below the Health Care sector average.
- Peak fcf margin was recorded in FY2020.
- Lowest fcf margin in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -585.0% | +4.5% |
| FY2024 | -612.8% | +45.5% |
| FY2023 | -1124.9% | -69.0% |
| FY2022 | -665.5% | +7.5% |
| FY2021 | -719.4% | -679.8% |
| FY2020 | -92.3% | +63.9% |
| FY2019 | -255.3% | -14.9% |
| FY2018 | -222.2% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026